metastatic renal cell carcinoma
Consider Neoadjuvant, Adjuvant Targeted Therapy for RCC
Neoadjuvant targeted therapy for renal cell carcinoma is less toxic than adjuvant targeted therapy, but both should ...
AUGUST 9, 2017
Alternate Sunitinib Schedule Is Feasible for mRCC
Although an alternate schedule of sunitinib in patients with mRCC failed to reduce grade 3 or higher toxicity ...
JULY 18, 2017
Individualized Sunitinib Dosing Provides Better Fit
Customized dosing of first-line sunitinib is safe and feasible, providing better response rates and survival in ...
JUNE 27, 2017
mRCC Control Seen After Immunotherapy Is Stopped
Orlando, Fla.—Patients with mRCC who respond to programmed death 1/programmed death ligand 1 checkpoint ...
MAY 9, 2017
Some Pts Benefit From Sunitinib Dose Escalation
Patients with mRCC who have disease progression on the standard dose of sunitinib may experience response with a ...
MARCH 7, 2017
Severe Systemic Inflammation Heralds Poor mRCC Outcomes
Outcomes in mRCC are poor if severe systemic inflammation (SSI) is present, according to a study presented at ASCO ...
MARCH 7, 2017
Response to Cytoreductive Nephrectomy May Predict Survival
A patient’s response to cytoreductive nephrectomy three months later may be a prognostic indicator of ...
FEBRUARY 15, 2017
PD Expression May Predict TKI-Related Outcomes of mRCC
Patients mRCC that expresses programmed death cells experience poorer overall and progression-free survival with ...
FEBRUARY 15, 2017
Lymphadenectomy Shows No Benefit for Metastatic RCC in Retrospective Analysis
Epidemiologic data from thousands of metastatic renal cell carcinoma patients indicates that lymphadenectomy ...
FEBRUARY 8, 2017